ARTICLE | Company News

Shkreli commits to 'modest' price reduction for Daraprim

November 6, 2015 3:27 AM UTC

Turing Pharmaceuticals AG (New York, N.Y.) CEO Martin Shkreli said in an interview with HIV activist Josh Robbins the company will commit to a "modest" price reduction of about 10% for toxoplasmosis drug Daraprim pyrimethamine by year end. Shkreli also said he is considering discounts on the order of 25-50% for smaller hospitals that cannot afford to stock Daraprim.

A Turing spokesperson told BioCentury further discussions on Daraprim discounts are "premature." ...